-
Electronic (PDF)
-
Site License
-
Enterprisewide
Cleveland BioLabs, Inc. - Product Pipeline Review - Q4 2010
GlobalData, November 2010, Pages: 49
Cleveland BioLabs, Inc. – Product Pipeline Review – Q4 2010
Summary
Global Market Direct’s pharmaceuticals report, “Cleveland BioLabs, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- Cleveland BioLabs, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Cleveland BioLabs, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Cleveland BioLabs, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Cleveland BioLabs, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Cleveland BioLabs, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Cleveland BioLabs, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Cleveland BioLabs, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Cleveland BioLabs, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Cleveland BioLabs, Inc. and identify potential opportunities in those areas.
List of Tables
List of Figures
Cleveland BioLabs, Inc. Snapshot
Cleveland BioLabs, Inc. Overview
Key Information
Key Facts
Cleveland BioLabs, Inc. – Research and Development Overview
Key Therapeutic Areas
Cleveland BioLabs, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Cleveland BioLabs, Inc. – Pipeline Products Glance
Cleveland BioLabs, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Cleveland BioLabs, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Cleveland BioLabs, Inc. – Drug Profiles
Curaxin CBLC102
Product Description
Mechanism of Action
R&D Progress
Protectan CBLB502
Product Description
Mechanism of Action
R&D Progress
Curaxin CBLC102
Product Description
Mechanism of Action
R&D Progress
CBLC137
Product Description
Mechanism of Action
R&D Progress
Curaxin CBLC102
Product Description
Mechanism of Action
R&D Progress
Protectan CBLB502
Product Description
Mechanism of Action
R&D Progress
Protectan CBLB612
Product Description
Mechanism of Action
R&D Progress
Cleveland BioLabs, Inc. – Pipeline Analysis
Cleveland BioLabs, Inc. – Pipeline Products by Therapeutic Class
Cleveland BioLabs, Inc. Pipeline Products By Target
Cleveland BioLabs, Inc. – Pipeline Products by Route of Administration
Cleveland BioLabs, Inc. – Pipeline Products by Molecule Type
Cleveland BioLabs, Inc. – Recent Pipeline Updates
Cleveland BioLabs, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Nov 01, 2010: Cleveland BioLabs Initiates Phase IB Trial For Prototype Curaxin CBLC102 In Russia
Oct 19, 2010: Cleveland BioLabs Receives Chinese Notice Of Patent Allowance For CBLB502
Oct 04, 2010: Cleveland BioLabs Receives First Patents For Protectan CBLB612 From South Africa And Eurasian Patent Organization
Sep 29, 2010: Cleveland BioLabs Announces Results Of Second Safety Study For CBLB502
Jul 22, 2010: Cleveland Biolabs' CBLB502 Receives FDA's Fast Track Status For Treatment Of Acute Radiation Syndrome
Jul 20, 2010: Cleveland BioLabs Announces Publication Of New Study On Curaxins Indicating Potential Antiviral Applications
May 10, 2010: Cleveland Biolabs Completes Dosing In Second Safety Study For CBLB502
Feb 24, 2010: Cleveland BioLabs Submits Response To DoD Request For Proposal For Radiation Countermeasure
Jan 28, 2010: Cleveland BioLabs Receives Grant Of European Patent For Radiation Protection Drug CBLB502
Jan 06, 2010: Cleveland BioLabs Receives First U.S. Patent For Radiation Protection Drug CBLB502
Financial Deals Landscape
Cleveland BioLabs, Inc., Deals Volume Summary, 2004 to YTD 2010
Cleveland BioLabs, Inc., Deals Summary By Region, 2004 to YTD 2010
Cleveland BioLabs, Inc., Deals Summary, 2004 to YTD 2010
Cleveland BioLabs, Inc. Detailed Deal Summary
Venture Financing
Cleveland BioLabs Secures $5.9 Million In Financing
Equity Offering
Cleveland BioLabs Completes Private Placement Of $5.43 Million
Cleveland Biolabs Forms Joint Venture With Bioprocess Capital
Cleveland BioLabs Enters Into Research Agreement With Roswell Park Cancer Institute
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
